In clinical trials, Velsipity helped 27% of patients taking it go into remission at 12 weeks and 32% at 52 weeks, significantly higher than the 7% of patients who received placebos at both time points. The pill also showed a benefit on other endpoints Pfizer studied, such as improvement based on measurements taken through an endoscope.
Pfizer set a list price of $6,164 for a 30-day supply of the once-daily pill, or about $75,000 a year. That is in line with oral treatments like Pfizer’s own Xeljanz and AbbVie’s Rinvoq, and less than the $100,000 annual price Bristol Myers set for Zeposia.
